Leerink Upgrades Replimune to Outperform, Sees High Odds of FDA Approval for Melanoma Therapy
Leerink upgrades Replimune to Outperform with $17 target, citing high odds of FDA accelerated approval for RP-1 melanoma therapy after 10-3 vote.
/ 185 items
#XY Analyst Up/Down↓
Oppenheimer Sees 215% Upside in Viking Therapeutics as VK2735 Options Expand Beyond Near-Term Readouts
Wall Street stays bullish on VKTX as Oppenheimer sees expanded opportunities for VK2735 beyond near-term readouts and funding into 2028.
Wells Fargo Initiates Coverage of Pyxis Oncology with $12 Target, Sees Shares Doubling on Fall Update
Dose cap de-risks MICVO as Wells Fargo starts Pyxis at Overweight with $12 target. Sees at least 2x upside on fall HNSCC update.
B. Riley Initiates Coverage on 4D Molecular with $37 Target — 267% Upside Potential
4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns
Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.
Piper Sandler: Intuitive Surgical Still Dominant in Soft-Tissue Robotics Despite J&J’s Ottava
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.